SCHEMBL4200148

SCHEMBL4200148

CC(CC1CCCCC1)NCc1ccccc1NC(=O)N1CCN(c2ccccc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.51
ALDH1A1 P00352 4/20 0.51
KDM4E B2RXH2 3/20 0.51
GAA P10253 3/20 0.51
HTT P42858 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.48
POLB P06746 2/20 0.47
HSD17B10 Q99714 1/20 0.47
TSHR P16473 1/20 0.43
MAPK1 P28482 3/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 1/20 0.42
HCRTR1 O43613 1/20 0.42
USP2 O75604 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
NAMPT P43490 1/20 0.42
RBP4 P02753 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4192826 0.93 MAPT (0.45) MAPTALDH1A1KDM4EGAAHTT
SCHEMBL4185987 0.89 KDM4E (0.46) MAPTALDH1A1KDM4EGAAHSD17B10
SCHEMBL4186491 0.88 CTSS (0.46) ALDH1A1KDM4EGAASMN1; SMN2HSD17B10
SCHEMBL4195525 0.87 KDM4E (0.50) MAPTALDH1A1KDM4ESMN1; SMN2HSD17B10
SCHEMBL4199612 0.86 POLB (0.41) MAPTALDH1A1KDM4EGAASMN1; SMN2
SCHEMBL4202203 0.85 KMT2A (0.49) ALDH1A1KDM4EGAASMN1; SMN2HSD17B10
SCHEMBL4192534 0.84 TRPV1 (0.43) MAPTALDH1A1KDM4EGAAHSD17B10
SCHEMBL4192548 0.82 KMT2A (0.47) ALDH1A1KDM4ESMN1; SMN2POLBHSD17B10
SCHEMBL4190300 0.81 PKM (0.49) ALDH1A1KDM4EGAASMN1; SMN2HSD17B10
SCHEMBL4708259 0.81 SMN1; SMN2 (0.51) MAPTALDH1A1KDM4EGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP claimed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US claimed
CN-101203504-A Antimicrobial agents RANBAXY LAB LTD (IN) 2008-06-18 CN claimed
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP disclosed
CN-101203504-B Antimicrobial agents RANBAXY LAB LTD 2012-11-14 CN disclosed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US disclosed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US disclosed
CN-101203504-A Antimicrobial agents RANBAXY LAB LTD (IN) 2008-06-18 CN disclosed
EP-1879877-A2 ANTIMICROBIAL AGENTS Ranbaxy Laboratories Limited (IN) 2008-01-23 EP disclosed
WO-2006117762-A2 ANTIMICROBIAL AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215764-A1 Antimicrobial agents TUFM, RPS17, HARS1 MAPT 2269/4885ALDH1A1 2744/4885KDM4E 3328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.